US stocks stumble as Moderna sinks on report questioning trial results


A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against Covid-19 - Reuters

NEW YORK (Reuters): The S&P 500 closed lower on Tuesday, as investors focused on a report questioning Moderna's recent coronavirus vaccine early-stage trial results, wiping out modest gains on the benchmark index in the last hour of trading.

Major averages fell to session lows in the wake of a report from STAT News that questioned the validity of the results of Moderna's vaccine trial, which the company had announced Monday.

Moderna Inc shares plunged after the report, and closed down 10.41%.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Moderna , clinical trials , Wall Street

   

Next In Business News

Cash purchase vs mortgage
The intriguing viability of themed rentals
DBKL’s tax moves on KLites questioned
Sime Darby Property's Elmina Lakeside Mall achieves 99% occupancy
Sime Darby Property's Elmina Lakeside Mall hits 99% occupancy
Ringgit likely to face cautious trading next week
GDA INCHES CLOSER TO 90% ACCEPTANCE
M&As in the spotlight
Bringing the outdoors in
Asia and EMs offer compelling value

Others Also Read